BNT163

BNT163 is BioNTech's experimental mRNA vaccine for preventing genital lesions caused by HSV-2 and potentially HSV-1. As of September 1, 2026, its Phase 1 study was active but no longer recruiting, with completion estimated for October 2026.

A small interim report found antibody responses and mostly mild-to-moderate short-term reactions in the first dose-escalation groups. That is early human evidence; it does not yet show that BNT163 prevents HSV infection, genital lesions, transmission, or recurrences in people.

BNT163 contains three pieces of messenger RNA packaged in lipid nanoparticles. They encode HSV-2 glycoproteins called gC2, gD2, and gE2, which were selected to prompt immune responses against viral entry, spread, and immune-evasion functions.

BioNTech identifies BNT163 as the first clinical candidate from its infectious-disease mRNA collaboration with the University of Pennsylvania. The published Penn animal studies help explain the scientific lineage, but they are not human BNT163 results.

The registered study's primary purpose is prevention. Parts A and B examine safety, tolerability, dose selection, and immune responses in adults without a history of symptomatic genital herpes. Part C examines safety and immune responses in adults who already have recurrent genital HSV-2.

The Phase 1 study began in December 2022 and ultimately enrolled 318 adults aged 18–55. The current record describes three sequential parts and lists the study as active, not recruiting.

The only public human-results report identified for this packet covers 48 participants in the first dose-escalation part. It reported blinded data through 28 days after the second vaccination, not the final study or the later cohorts.

In the 48-person interim report, local and systemic reactions were mostly mild or moderate, and no prespecified safety pausing or stopping rule was met during the period covered by the report. Those findings are preliminary and do not supply a final comparative safety analysis.

Binding-antibody levels to the encoded antigens showed increasing trends after the first two vaccinations, and HSV-2 neutralizing antibodies were induced in the dose groups available for analysis. The report did not show whether vaccinated participants had fewer infections, lesions, recurrences, or transmission events.

The most defensible evidence-maturity label is early human evidence. BNT163 reached human testing and produced measurable immune responses in the reported early groups, but immune activity is not the same as demonstrated prevention or therapeutic benefit.

As of September 1, 2026, BNT163 was not an approved or available HSV vaccine. Its current record supports tracking an ongoing clinical program, not predicting that the candidate will work, advance, or become available.

Recent BioNTech filings continued to list the program, and the registry described its Phase 1 study as active but not recruiting as of September 1, 2026. That does not establish what BioNTech will decide after the study ends.

The only confirmed near-term event in the checked record was continued study follow-up toward an estimated October 2026 completion. Estimated dates are plans, not results, and no subsequent development stage had been confirmed as of September 1, 2026.